Hari V. Kalluri
AbbVie (United States)(US)
Publications by Year
Research Areas
Renal Transplantation Outcomes and Treatments, HIV/AIDS drug development and treatment, Pharmacological Effects and Toxicity Studies, Hepatitis C virus research, Opioid Use Disorder Treatment
Most-Cited Works
- → Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study(2023)121 cited
- → Current state of renal transplant immunosuppression: Present and future(2012)78 cited
- → An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy(2017)65 cited
- → Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)(2020)52 cited
- → Gestational changes in buprenorphine exposure: A physiologically‐based pharmacokinetic analysis(2018)36 cited
- → Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study(2020)28 cited
- → A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration(2017)28 cited
- → Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants(2022)23 cited
- → Low vitamin D exposure is associated with higher risk of infection in renal transplant recipients(2017)19 cited
- → Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study(2023)10 cited